NEXALIN TECHNOLOGY INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 70.59 K

LB filings
2025.08.06 17:55
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 70.59 K.

EPS: As of FY2025 Q2, the actual value is USD -0.1.

EBIT: As of FY2025 Q2, the actual value is USD -1.621 M.

Segment Revenue

  • Total Revenues: For the three months ended June 30, 2025, total revenues were $70,588, compared to $26,840 for the same period in 2024, representing a 163% increase. For the six months ended June 30, 2025, total revenues were $111,603, compared to $105,511 for the same period in 2024, representing a 6% increase.

Operational Metrics

  • Net Loss: For the three months ended June 30, 2025, the net loss was -$1,580,987, compared to -$1,284,493 for the same period in 2024. For the six months ended June 30, 2025, the net loss was -$3,569,324, compared to -$2,325,650 for the same period in 2024.
  • Gross Profit: For the three months ended June 30, 2025, gross profit was $47,750, compared to $19,593 for the same period in 2024. For the six months ended June 30, 2025, gross profit was $75,207, compared to $89,108 for the same period in 2024.
  • Operating Expenses: Total operating expenses for the three months ended June 30, 2025, were $1,668,608, compared to $1,316,614 for the same period in 2024. For the six months ended June 30, 2025, total operating expenses were $3,707,290, compared to $2,459,841 for the same period in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was -$2,343,379, compared to -$2,009,704 for the same period in 2024.
  • Net Cash Provided by (Used in) Investing Activities: For the six months ended June 30, 2025, net cash used in investing activities was -$2,446,183, compared to $2,278,270 provided by investing activities for the same period in 2024.
  • Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $4,646,397, compared to $0 for the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: The company plans to conduct clinical trials for the Gen-2 SYNC and Gen-3 HALO devices in the U.S. and continue consultations with the FDA as part of the pre-submission process. If FDA clearance is obtained, commercialization of these devices for sale in the U.S. and other territories will begin.
  • Non-Core Business: The company is developing a virtual clinic to allow physicians to diagnose mental health issues in a tele-psychiatry virtual platform, which will include the prescription of the Gen-3 HALO headset for home use.
  • Priority: The company is focused on obtaining FDA clearance for its new devices and expanding its market presence in the U.S. and internationally, with ongoing clinical trials and regulatory submissions being key components of its strategy.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.